Among different glioma subtypes, AR positivity was found in fourteen patients diagnosed with GBM IDH-wildtype grade 4 (66.7%), in four cases with astrocytoma IDH-mutant grade 2 (19%), in two cases of astrocytoma IDH-mutant grade 3 (9.5%) and in one case of oligodendroglioma IDH-mutant and 1p19q codeleted grade 2 (4.8%) (Table 1 and Figure 1). This evidence concerns the gene IDH2 and central nervous system cancer.